Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis

doi:10.19852/j.cnki.jtcm.20230517.002

Abstract

Abstract:

OBJECTIVE: To evaluate the effectiveness and safety of Xuebijing injection (XBJ) on coronavirus disease 2019 (COVID-19) in patients.

METHODS: Related studies on multiple biological databases and websites were searched up to December 11, 2021 without language and publication time restrictions. Review Manager V.5.3 and Stata 14 software were used for data analysis.

RESULTS: Seven studies were finally included. The Meta-analysis showed that compared with the routine treatment alone, XBJ combined with the routine treatment can reduce the 28-day mortality (OR = 0.3, 95% CI: 0.12, 0.74), C-reactive protein (MD = —12.8, 95% CI: —23.13, —3.46), erythrocyte sedimentation rate (MD = —9.32, 95% CI: —14.66, —3.98) and interleukin-6 (SMD = —0.6, 95% CI: —1.04, —0.17) levels and increase the leukocyte (MD = 0.73, 95% CI: 0.42, 1.04) and lymphocyte count (MD = 0.18, 95% CI: 0.07, 0.29) in peripheral blood; additionally, it has no obvious side effects (OR = 1.11, 95% CI: 0.65, 1.9). There was no evidence that the XBJ combined therapy can improve the nucleic acid conversion rate and computed tomography improvement rate of COVID-19 patients.

CONCLUSIONS: Preliminary evidence suggests that XBJ combined with routine treatment seems to be more effective than routine treatment for patients with COVID-19. Limited by the number and quality of included papers, this finding still needs further validation by more studies.

Key words: COVID-19, Xuebijing injection, safety, treatment outcome, Meta-analysis, systematic review

SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, ZHOU Jian. Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 631-639.

Figures/Tables 4

References 35.

1.	Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-42.
2.	Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect 2020; 80: e14-7.
3.	WHO Coronavirus (COVID-19) Dashboard, 2021-11-22, cited 2021-11-22. Available from URL: https://covid19.who.int/.
4.	Xu X, Ong YK, Wang Y. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Mil Med Res 2020; 7: 22. DOI PMID
5.	Li C, Wang P, Zhang L, et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a Meta-analysis of randomized controlled trials. J Ethnopharmacol 2018; 224: 512-21. DOI PMID
6.	Song Y, Yao C, Yao Y, et al. Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med 2019; 47: e735-43. DOI URL
7.	National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of COVID-19 (5th Edition), 2020-02-04, cited 2021-11-22. Available from URL: www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf.
8.	Ma Q, Qiu M, Zhou H, et al. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res 2020; 160: 105073.
9.	Zheng WJ, Yan Q, Ni YS, et al. Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology. Bio Data Min 2020; 13: 17.
10.	Zheng Y, Liu ZQ, Zhu XQ, Wang BL. To investigation of the mechanism of Xuebijing injection in COVID-19 treatment based on network pharmacology and molecular docking. Zhong Guo Bi Jiao Yi Xue Za Zhi 2020; 30: 57-64.
11.	Li S, Lu W, Zhao XQ, et al. Therapeutic effect observation on different doses of Xuebijing injection in treatment of severe Corona Virus Disease 2019. Zhong Guo Zhong Xi Yi Jie He Ji Jiu Za Zhi 2020; 27: 267-70.
12.	Luo Z, Chen W, Xiang M, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med 2021; 42: 101305. DOI URL
13.	Wen L, Zhou Z, Jiang D, Huang K. Effect of Xuebijing injection on inflammatory markers and disease outcome of Coronavirus Disease 2019. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2020; 32: 426-9.
14.	Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097. DOI URL
15.	Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. DOI URL
16.	Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network Meta-analysis. Lancet 2019; 394: 939-51. DOI PMID
17.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in Meta-analyses. Eur J Epidemiol 2010; 25: 603-5. DOI PMID
18.	Campbell M, McKenzie JE, Sowden A, et al. Synthesis without Meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 2020; 368: l6890.
19.	Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. DOI PMID
20.	Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490. DOI URL
21.	Chen L, Liu H, Xiao G. The curative effect of Xuebijing injection in the treatment of new coronary pneumonia and its influence on CRP. Zhong Guo Chu Fang Yao 2020; 18: 110-1.
22.	Guo H, Zheng J, Huang G, et al. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. Ann Palliat Med 2020; 9: 3235-48. DOI PMID
23.	Liu K, Fu M, Zhang ZP, Zhang Z. The clinical efficacy of Xuebijing on patients with 2019 coronary pneumonia. Compilation of National Scientific Research Theory and Academic Research Achievements (IV), 2020-04-08, Beijing, China. Beijing: China Global Culture Press, 2020: 395-38.
24.	Zhang C, Li Z, Zhang S, Wang W, Jiang X. Clinical observation of Xuebijing in the treatment of COVID-19. Zhong Guo Yi Yuan Yao Xue Za Zhi 2020; 40: 964-7.
25.	Liu X, Song Y, Guan W, et al. A multicenter prospective cohort study of Xuebijing injection in the treatment of severe coronavirus disease 2019. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2021; 33: 774-8.
26.	Jiang M, Zhou M, Han Y, et al. Identification of NF-κB Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF. J Ethnopharmacol 2013; 147: 426-33. DOI PMID
27.	Liu Y, Tian X, Cui M, Zhao S. Safflower yellow inhibits angiotensin Ⅱ-induced adventitial fibroblast proliferation and migration. J Pharmacol Sci 2014; 126: 107-14. DOI URL
28.	Wang Q, Wu X, Tong X, Zhang Z, Xu B, Zhou W. Xuebijing ameliorates sepsis-induced lung injury by downregulating HMGB1 and RAGE expressions in mice. Evid Based Complement Alternat Med 2015; 2015: 860259.
29.	Wang Q, Mei J, Wang C, et al. Meta analysis on the treatment of coronavirus disease 2019 by Traditional Chinese and Western Medicine. Zhong Hua Wei Zhong Bing Ji Jiu Yi Xue 2021; 33: 714-20.
30.	Shao M, Liu B, Wang JQ, et al. Effect of Xuebijing injection on T helper 17 and CD4+ CD25+ regulatory T cells in patients with sepsis. Zhong Guo Wei Zhong Bing Ji Jiu Yi Xue 2011; 23: 430-4.
31.	Yao RQ, Ren C, Wang LX, Dong N, Wu Y, Yao YM. Influence of Xuebijing injection and its component paeoniflorin on immune function and survival rate of septic rats. Zhong Hua Shao Shang Za Zhi 2020; 36: 658-64.
32.	Wang YB, Wang Q, Yao YM, Sheng ZY, Liu YF. Effect of Xuebijing injection on systemic lupus erythematosus in mice. Chin J Integr Med 2013; 19: 675-82. DOI URL
33.	Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a Meta-analysis. Cytometry A 2020; 97: 772-6. DOI URL
34.	DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem Biophys Res Commun 2021; 538: 211-7. DOI URL
35.	Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res 2020; 69: 379-88. DOI PMID

Study	Study design	Cases (E/C)	Age (years) (range, mean ± SD)	Sex (M/F)	State of disease	Intervantion	Duration (d)	Outcomes
Luo et al 2021¹²	RCT	29/28	E: 60.26±15.62 C: 56.35±18.28	NP	Severe	E: XBJ (50 mL, twice a day)+RT C: Saline+RT	14	②③④⑧⑨⑩??
Wen et al 2020¹³	RCT	20/20/20	E1: 47.1±5.2 E2: 49.1±4.8 C: 47.7±5.7	E1: 12/8 E2: 11/9 C: 9/11	Severe	E1: XBJ (100 mL, twice a day)+RT E2: XBJ (50 mL, twice a day)+RT C: RT	7	①②③⑤⑥⑦⑧
Chen et al 2020²¹	RCT	15/15	E: 42.6±3.5 C: 42.6±3.5	E: 8/7 C: 9/6	NP	E: XBJ (100 mL, twice a day)+RT C: RT	14	①⑧
Guo et al 2020²²	Case-control study	16/16	E: 46-57, 52 C: 44-59, 54	E: 9/7 C: 11/5	Mild and severe	E: XBJ (100 mL, twice a day)+RT C: RT	7	①②③④⑦??
Liu et al 2020²³	RCT	10/10	37-83, 66.8	12/8	Mild	E: XBJ (50 mL, twice a day)+RT C: RT	3	①②③⑤⑧?
Zhang et al 2020²⁴	Case-control study	22/22	E: 25-73 C: 19-67	E: 10/12 C: 12/10	Common	E: XBJ (50 mL, twice a day)+RT C: RT	7	①②③⑥⑦⑧
Liu et al 2021²⁵	Multicenter prospective cohort study	72/72	E: 63.5±10.9 C: 65.7±7.9	E: 51/21 C: 54/18	Severe	E: XBJ (100 mL, twice a day)+RT C: RT	1-28	⑧⑨⑩

Study	Study design	Cases (E/C)	Age (years) (range, mean ± SD)	Sex (M/F)	State of disease	Intervantion	Duration (d)	Outcomes
Luo et al 2021¹²	RCT	29/28	E: 60.26±15.62 C: 56.35±18.28	NP	Severe	E: XBJ (50 mL, twice a day)+RT C: Saline+RT	14	②③④⑧⑨⑩??
Wen et al 2020¹³	RCT	20/20/20	E1: 47.1±5.2 E2: 49.1±4.8 C: 47.7±5.7	E1: 12/8 E2: 11/9 C: 9/11	Severe	E1: XBJ (100 mL, twice a day)+RT E2: XBJ (50 mL, twice a day)+RT C: RT	7	①②③⑤⑥⑦⑧
Chen et al 2020²¹	RCT	15/15	E: 42.6±3.5 C: 42.6±3.5	E: 8/7 C: 9/6	NP	E: XBJ (100 mL, twice a day)+RT C: RT	14	①⑧
Guo et al 2020²²	Case-control study	16/16	E: 46-57, 52 C: 44-59, 54	E: 9/7 C: 11/5	Mild and severe	E: XBJ (100 mL, twice a day)+RT C: RT	7	①②③④⑦??
Liu et al 2020²³	RCT	10/10	37-83, 66.8	12/8	Mild	E: XBJ (50 mL, twice a day)+RT C: RT	3	①②③⑤⑧?
Zhang et al 2020²⁴	Case-control study	22/22	E: 25-73 C: 19-67	E: 10/12 C: 12/10	Common	E: XBJ (50 mL, twice a day)+RT C: RT	7	①②③⑥⑦⑧
Liu et al 2021²⁵	Multicenter prospective cohort study	72/72	E: 63.5±10.9 C: 65.7±7.9	E: 51/21 C: 54/18	Severe	E: XBJ (100 mL, twice a day)+RT C: RT	1-28	⑧⑨⑩

[1]	FAN Rong, HE Haoyu, TANG Tao, CUI Hanjin. Long-term effects of Qingfei Paidu decoction (清肺排毒汤) in patients with coronavirus disease 2019 acute pneumonia after treatment: a protocol for systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1068-1071.
[2]	ZHANG Meizhen, HAO Xiaohui, TANG Yiting, CHEN Yupeng, HE Puyu, ZHAO Liming, PANG Bing, NI Qing. Efficacy and safety of Buyang Huanwu decoction (补阳还五汤) for diabetic peripheral neuropathy: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 841-850.
[3]	LUO Xin, XIE Jing, HUANG Li, GAN Wenfan, CHEN Ming. Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 429-440.
[4]	ZHANG Yuehong, SHAO Xianzhi, ZHAO Qianlong, ZHAN Hualong, ZHANG Jianhua, DU Sisi, CHEN Jing, LIU Yingfang, ZHOU Haiwang, CHEN Xinsheng, HONG Ying, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness of Xiangsha Liujun pills (香砂六君丸) on decreased digestive function in convalescent patients of coronavirus disease 2019: a randomized, double blind, placebo controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 552-558.
[5]	XU Guihua, CHEN Feifei, ZHANG Wei, WU Yingen, CHEN Xiaorong, SHI Kehua, WANG Zhenwei, SHI Miaoyan, ZHANG Xing, LU Yunfei, YUAN Weian, LYU Hua, CHEN Xuan. Effectiveness of Traditional Chinese Medicine on coronavirus disease 2019 in 92 patients: a retrospective study [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 582-587.
[6]	YANG Cunqing, LIAN Fengmei, YANG Guiping, HUANG Yufeng, ZHANG Shuangbin, WANG Jianghua, ZHOU Jing, GUO Dongqing, SHEN Chuanyun, YE Tiansong, FU Aojie, LI Xiaoli, CHEN Le, ZHANG Huifeng, TU Qiyin, WANG Ying, YANG Wenzhe, TONG Xiaolin, BA Yuanming. Effectiveness of Xiaoyao capsule (逍遥丸) on sleep disorders and mood disturbance in patients in recovery from coronavirus disease 2019: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 343-351.
[7]	ZHANG Yuehong, DONG Dandan, YAN Youqin, ZHANG Hao, WANG Guangli, ZHOU Wei, LI Wei, QIU Li, LI Tingming, LIU Quan, XIA Ping, MAO Lina, YANG Danlin, YANG Lu, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness and safety of Jinshuibao capsules (金水宝胶囊) in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 134-139.
[8]	AN Xuedong, MAO Lina, XIA Ping, SU Wen, WANG Beibei, KOU Leiya, ZHANG Zequan, QI Meng, HU Song, CHEN Jing, LI Xiujuan, LIU Jinwei, ZHOU Juan, QIAO Jie, LUO Dan, LUO Guangwei, YAN Youqin, YANG Guiping, DONG Dandan, ZHOU Wei, TAO Junxiu, JIN De, TONG Xiaolin, WEI Li. Effects of Shengmai Yin (生脉饮) on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 140-145.
[9]	LI Ximeng, KANG Yuan, LI Wenjing, LIU Zhuangzhuang, XU Zhenlu, ZHANG Xiaoyu, CAI Runlan, GAO Yuan, QI Yun. Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 51-59.
[10]	ZHU Qingguang, ZHANG Shuaipan, LI Jingxian, SUN Wuquan, CHENG Wei, ZHAN Chao, CHENG Yanbin, FANG Lei, FANG Min. Effectiveness of Liu-zi-jue exercise on coronavirus disease 2019 in the patients: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2022, 42(6): 997-10053.
[11]	ZHOU Yingyan, LIANG Huasheng, YAN Jingyao, HE Xiaohong, PAN Lili, LI Xue, CHEN Xianghong, CHEN Xiumin, YANG Aicheng, HUANG Qingchun. Effectiveness and safety of tripterygium glycosides tablet (雷公藤多苷片) for lupus nephritis: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 671-680.
[12]	AN Xuedong, ZHANG Qing, TAO Junxiu, LI Li, CHEN Yun, LI Kejian, HE Jing, LIU Ru, GUO Juan, ZHANG Jia, ZHU Hui, LIAN Fengmei, LI Xiaodong. Shugan Jieyu capsule (舒肝解郁胶囊) improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized, double-blind, placebo-controlled trial [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 803-809.
[13]	LIN Yi, LI Xun, WANG Zi, ZHENG Xiaoran, HANG Haiyan, LI Lingling. Efficacy and safety of external application of Chinese herbal medicine for psoriasis vulgaris: a systematic review of randomized controlled trials [J]. Journal of Traditional Chinese Medicine, 2022, 42(4): 493-504.
[14]	HUANG Yusi, YANG Jiju, LI Xinyi, HAO Huifeng, LI Chong, ZHANG Fan, LIN Haiming, XIE Xianfei, HE Ke, TIAN Guihua. Effectiveness and safety of electroacupuncture for the treatment of pain after laparoscopic surgery: a systematic review [J]. Journal of Traditional Chinese Medicine, 2022, 42(4): 505-512.
[15]	CHEN Huang, SHI Lushaobo, SHI Zengping, XIA Yi, WANG Dong. Factors influencing physician's behavioral intention to use Traditional Chinese Medicine to treat coronavirus disease 2019 based on the theory of planned behavior [J]. Journal of Traditional Chinese Medicine, 2022, 42(4): 633-6400.

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us